| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -1.0 | -0.5 |
| EPS (diluted, $ a share) | $-0.14 | $-0.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mustang Bio, Inc.: key numbers
- Share price
- $0.3900Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mustang Bio, Inc.
All →Mustang Bio Nasdaq/NYSE Compliance Notice
Mustang Bio received a second 180-day grace period from Nasdaq, until April 12, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company intends to monitor its stock price and may effect a reverse stock split if necessary to maintain its listing on the Nasdaq Capital Market.
- Counterparty
- Nasdaq
- Term
- 180 days